Compare Ascendis Pharma A/S (ASND) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Baker Hughes Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Baker Hughes Co trades at $58.34 (market cap $57.10B). The key difference: Baker Hughes Co is far larger — about 3.2× Ascendis Pharma A/S's market cap, and Baker Hughes Co pays a 1.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BKR | |
|---|---|---|
Market Cap | $17.74B | $57.10B |
Sector | Health | Energy |
52-Week High | $277.18 | $69.67 |
52-Week Low | $163.32 | $38.68 |
Enterprise Value | $18.11B | $58.50B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Baker Hughes (BKR) trades at $57.56, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with P/E of 18.39, ROE of 17.14%, and consistent revenue growth from $21.2B in 2022 to $27.7B in 2025. Recent contract wins with Cheniere and Kodiak Gas Services highlight expansion in LNG and power infrastructure, supporting long-term growth prospects.
BKR presents a compelling investment case with analyst consensus price target of $73.45 (27% upside) and 66.7% buy ratings. Key opportunities include LNG infrastructure expansion and energy transition projects, while risks involve oil price volatility and execution of the $13.6B Chart Industries acquisition. The stock's current valuation appears reasonable given earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
